10-Q · August 4, 2026
Travere delivered strong Q2 revenue growth, with $169.584 million of revenue led by $141.078 million in FILSPARI sales, and moved to approximately $1.780 million of operating income. However, GAAP EPS was a $0.37 loss…
TVTX earnings analysis
10-Q · Filed November 2, 2026 · Our reading of the company's report
The latest report
Travere delivered strong commercial momentum, with Q3 revenue of $224.6 million up 36.1% year over year and FILSPARI sales of $200.2 million up 120%. However, diluted EPS was negative $0.31, down from positive $0.28 a…
Read full summary
Travere delivered strong commercial momentum, with Q3 revenue of $224.6 million up 36.1% year over year and FILSPARI sales of $200.2 million up 120%. However, diluted EPS was negative $0.31, down from positive $0.28 a year earlier, and a $113.1 million civorebrutinib-related charge contributed to a $52.3 million net loss. Liquidity was $471.8 million against $620 million of long-term debt, while the FDA promotional letter, potential 100% tariffs, and sparsentan API-supply exposure add material execution risks.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.31
- Segment
- FILSPARI: $200.2 million of sales, up 120% year over year; other revenue implied at approximately $24.4 million based on total revenue of $224.6 million.
What stood out
-
Revenue accelerated and beat consensus
Third-quarter revenue was $224.6 million, up approximately 32.1% from $170.0 million in Q2 2026 and 36.1% from $165.0 million in Q3 2025. Revenue exceeded consensus of $194.7 million by $29.8 million.
-
FILSPARI remained the growth engine
FILSPARI sales reached $200.2 million, increasing 120% year over year and representing approximately 89% of total revenue of $224.6 million.
-
EPS improved sequentially but fell year over year
Reported diluted EPS was negative $0.31 versus negative $0.37 in Q2 2026, an improvement of $0.06 per share, but declined $0.59 from positive $0.28 in Q3 2025.
-
Liquidity remained substantial
Cash equivalents and marketable debt securities totaled approximately $471.8 million at September 30, 2026, providing a substantial liquidity position despite ongoing development and commercialization spending.
-
Debt structure is long term
Total debt was approximately $620 million, all classified as long term, creating meaningful future debt-service and refinancing obligations relative to the $471.8 million of cash equivalents and marketable debt securities.
-
Inflation has not changed current outlook
Management stated that inflationary pressures have primarily affected operations through increased labor costs, but that inflation had not affected the company’s current outlook or business objectives.
What to watch
-
FDA promotion letter threatens FILSPARI execution
A July 28, 2026 FDA untitled letter asserted that a FILSPARI professional visual aid contained false or misleading safety and efficacy claims. The company is engaging with FDA to resolve the matter, creating regulatory and commercialization risk for a product generating $200.2 million of quarterly sales.
-
Large licensing charge drove quarterly loss
The company recorded a $113.1 million civorebrutinib-related in-process research and development charge, contributing to a $52.3 million net loss and reported diluted EPS of negative $0.31.
-
Debt and funding needs constrain flexibility
The company had approximately $620 million of total debt outstanding at quarter-end versus $471.8 million of cash equivalents and marketable debt securities; management stated it may need additional equity or debt financing if results of operations are insufficient.
-
Sparsentan API supply exposure increased
The company’s current primary sparsentan API supplier was added to the U.S. Department of Defense Section 1260H list in June 2026. Although a court preliminarily enjoined enforcement in August 2026, the company may need to qualify an alternative supplier, potentially increasing costs or disrupting supply.
-
Potential 100% pharmaceutical tariffs
A presidential proclamation imposes 100% tariffs on certain patented pharmaceutical products and ingredients, and the company stated it remains uncertain whether FILSPARI will qualify for a 0% orphan-drug tariff rate.
-
Pegтibatinase development remains execution-sensitive
The Phase 3 HARMONY Study enrollment pause followed failure to achieve the desired drug-substance profile during initial scale-up in September 2024; enrollment restarted in Q1 2026, but the company cannot assure completion on schedule or success.
Management's outlook
No quantitative revenue or EPS guidance, or change to prior outlook, was provided in the filing materials.
Earlier filings 4
10-Q · May 4, 2026
Travere Therapeutics reported total revenue of $127.2 million for Q1 2026, up 45.5% year-over-year, bolstered by a notable increase in FILSPARI sales, which rose 88% to $105.2 million. The company reported positive EPS…
10-K · February 19, 2026
Travere showed strong commercial and milestone-driven revenue growth in 2025 (quarterly sales of $82M, $114M, $165M and $130M), driven by FILSPARI approvals and partnership milestones, but Q4 2025 operating performance…
10-Q · October 30, 2025
Travere reported a strong operational quarter: revenue of $164,859,000 (Q3 2025) vs $62,898,000 a year earlier and operating income of $24,931,000 versus an operating loss of $(56,149,000) in Q3 2024. Diluted EPS was…
Smart money in TVTX
Totals from the last full session. Insider and politician figures cover 90 days.
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.
See every TVTX trade live.
The free pages stop at the last full session. Trader shows every trade as it prints.
Start tracking No card needed.